Sharing a high quality and thoughtful post from

New Post Public Reply Private Reply Replies (1) Message Board
mtruong34
775
Sharing a high quality and thoughtful post from YMB:

After another few months of following this board, I am once again sharing my perspective as a regulatory professional who has filed eINDs for antiviral monoclonal antibodies during a previous public health emergency.

In my view, the granting of an open label expansion for the CD12 trial is a clear signal that FDA sees a favorable risk/reward basis for continued use of Leronlimab. As some have pointed out, there is still a possibility that the trial may not meet its endpoint on a statistical basis, and it is true that there are examples of drugs which were granted open-label extensions without going on to be approved. However, the explicit purpose of having a study with DSMC interim reviews is to close a trial as soon as it becomes clear that there will be a statistical failure; as we know, the DSMC interim recommendations for CD12 have all been positive and most recently indicated that the statistical threshold may be met before full enrollment, which has been achieved at this point regardless.

I’ve also spent some time thinking about the additional criteria FDA specified to allow continued eIND use of Leronlimab outside of the new open label arm for CD12, which equates to more restrictive PEEP/PaO2 thresholds that will effectively exclude less severe patients from receiving the drug outside of CD12 trial sites. In my past experience with emergency use, FDA’s position was that eIND data is the least reliable/interpretable data and that companies should avoid using eINDs if at all possible. Data collected under a protocol such as CD12 is much higher quality and allows all parties (FDA, the drug company, the doctors, etc) to make informed decisions based on the results; in contrast, eIND data is uncontrolled and is collected by medical staff who may not be trained for/experienced with the investigational product, often using different standards of care and outcome collection procedures for each individual eIND patient. Therefore, an explanation for why FDA has advised Cytodyn to exclude all but the most severely ill patients from further eIND use may be because data collected for less severe patients outside of the CD12 protocol is likely to be uninterpretable, but the drug may still provide benefit to these people who currently have no other treatment options.

There are some other posters that have covered this in detail, and I’ve seen some compelling points why this might be a positive sign; on the flip side, nothing in from my own experience or on this board has convinced me that this could be a negative development. However, all we can do is speculate until we hear more from Cytodyn or FDA.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s Second IND Adds Proof to Its Glue Platform

Updated Category News Views 25

Two IND acceptances from one long-running alliance is not nothing, especially in a drug-discovery business where plenty of polished platform talk never makes it to the clinic. Evotec has cleared that modest but meaningful bar again with Bristol Myers Squibb: a second molecular-glue candidate has received FDA acceptance for an Investigational New Drug application. The...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 125

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 154

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 32

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 69

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 57

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 39

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 50

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 194

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading

Top 5 Most Recently Viewed Articles

AMSURG Expands Its Network with Pinnacle Surgery Center Acquisition

Updated Category News Views 950

AMSURG Expands Its Network with Pinnacle Surgery Center Acquisition AMSURG, a prominent independent leader in ambulatory surgery center services, recently achieved a significant milestone by acquiring Pinnacle Surgery Center. This acquisition boosts AMSURG's presence in the healthcare industry, particularly in providing high-quality surgical care to communities. Overview...

Continue Reading
Montauk Renewables Announces Q2 2025 Conference Call Details

Updated Category News Views 192

Montauk Renewables Schedules Q2 2025 Conference Call Montauk Renewables, Inc. (NASDAQ: MNTK), a leading renewable energy company specializing in biogas management, will host its second quarter 2025 conference call on a Thursday morning. This session is set for August 7, 2025, at 8:30 a.m. ET, where they will present their financial results for the period ending June 30,...

Continue Reading
MaxCyte Earnings Report: What Investors Should Know

Updated Category News Views 157

MaxCyte's Earnings Announcement Overview MaxCyte (NASDAQ: MXCT) is gearing up for its quarterly earnings report. Investors are keen to see the results, especially when it comes to their earnings per share (EPS) expectations. Anticipated Earnings Performance Analysts are predicting that MaxCyte will report an EPS of $-0.10. This figure is crucial as it sets the stage for...

Continue Reading
Pluxee Expands Employee Benefits with Benefício Fácil Acquisition

Updated Category News Views 239

Pluxee Strengthens Its Presence in Brazil Through Strategic Acquisition Pluxee has made a significant move to solidify its operations in Brazil by acquiring 100% of Benefício Fácil, a leading provider of employee mobility benefits. This acquisition marks a pivotal step in reinforcing Pluxee’s position within the dynamic Brazilian market. Details of the Acquisition The...

Continue Reading
Carlyle Credit Income Fund Announces Public Offering Details

Updated Category News Views 312

Carlyle Credit Income Fund Prices New Offering of Preferred Shares In a significant development in the investment community, Carlyle Credit Income Fund (the "Fund") (NYSE: CCIF) has unveiled the details of its latest public offering. The Fund has successfully priced an underwritten public offering for 1.2 million shares of its Series D Preferred Shares, which come with a...

Continue Reading